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T-type calcium channel blockers have been previously shown
to protect glomeruli from hypertension by regulating renal
arteriolar tone. To examine whether blockade of these
channels has a role in protection against tubulointerstitial
damage, we used a stereo-selective T-type calcium channel
blocker R()-efonidipine and studied its effect on the
progression of this type of renal injury in spontaneously
hypertensive rats that had undergone subtotal nephrectomy.
Treatment with racemic efonidipine for 7 weeks significantly
reduced systolic blood pressure and proteinuria. The
R()-enantiomer, however, had no effect on blood pressure
but significantly reduced proteinuria compared to vehicle-
treated rats. Both agents blunted the increase in
tubulointerstitial fibrosis, renal expression of a-smooth
muscle actin and vimentin along with transforming growth
factor-b (TGF-b)-induced renal Rho-kinase activity seen in the
control group. Subtotal nephrectomy enhanced renal T-type
calcium channel a1G subunit expression mimicked in
angiotensin II-stimulated mesangial cells or TGF-b-stimulated
proximal tubular cells. Our study shows that T-type calcium
channel blockade has renal protective actions that depend
not only on hemodynamic effects but also pertain to
Rho-kinase activity, tubulointerstitial fibrosis, and
epithelial–mesenchymal transitions.
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Voltage-dependent Ca2þ channels are categorized into two
subfamilies by their electrophysiological properties: a high
voltage-activated Ca2þ channel family, including P-/Q-, L-,
N-, and R-type Ca2þ channels, and low-voltage-activated
Ca2þ channels, which correspond to T-type Ca2þ channels
(TCCs).1 Although L-type Ca2þ channel blockers (L-CCBs),
including nifedipine, are widely prescribed for the treatment
of hypertension, there is some concern that L-CCBs might
aggravate renal damage.2 As L-type Ca2þ channels (LCCs)
prevail predominantly in the afferent arteriole but are
sparsely expressed in the efferent arteriole,3,4 L-CCBs would
dilate the afferent arteriole preferentially and thus might
accelerate glomerular hypertension if the hypotensive effect is
insufficient. In contrast, as TCCs are expressed in both
afferent and efferent arterioles,5 it is reasonably conjectured
that TCC blockers (T-CCBs) protect glomeruli from systemic
hypertension by regulating renal arteriolar tone.4,6–8 We
previously reported that efonidipine, a CCB with a blocking
activity on both TCCs and LCCs,9 ameliorated proteinuria
more potently than nifedipine in subtotally nephrectomized
spontaneously hypertensive rats (SHR) despite similar blood
pressure-lowering effects.10 Although this result suggests that
the T-CCB improves the progression of renal injury, it
remains to be determined whether this effect of efonidipine is
mediated by the specific blockade of TCCs because
efonidipine has substantial effects on LCCs as well.
Furthermore, the role of the TCC in mediating the
tubulointerstitial changes in the development of renal injury
has not been examined.
Several lines of investigations have witnessed that the Rho/
Rho-kinase pathway is activated in progressive renal
injury.11–13 Small-molecule G protein, Rho, and its effector
Rho-kinase contribute significantly to the vascular contractile
response as well as various cellular functions, including cell
adhesion/migration and proliferation.14–16 We have recently
demonstrated that the Rho/Rho-kinase pathway participates
in the regulation of renal afferent and efferent arteriolar tone
and glomerular filtration.17 Furthermore, the long-term
Rho-kinase inhibition by fasudil reduces proteinuria in
the rat remnant kidney model.11 In this regard, it has been
o r i g i n a l a r t i c l e http://www.kidney-international.org
& 2008 International Society of Nephrology
Received 2 February 2007; revised 1 November 2007; accepted 13
November 2007; published online 16 January 2008
Correspondence: K Hayashi, Department of Internal Medicine, School of
Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582,
Japan. E-mail: khayashi@sc.itc.keio.ac.jp
826 Kidney International (2008) 73, 826–834
reported that increases in intracellular Ca2þ concentration
are associated with the activation of Rho-kinase in several
types of vascular beds.18,19 Furthermore, in mesangial cells,
efonidipine, but not nifedipine, suppresses nuclear factor-kB
expression,20 which is also a target for the Rho/Rho-kinase
pathway.21 No studies have been conducted, however,
examining the role of the TCC-mediated signaling pathway
in the activation of Rho-kinase and the subsequent impact on
renal injury.
Efonidipine is the raceme of R()-enantiomer and
S(þ )-enantiomer, and these isomers have been recently
isolated. The R()-enantiomer of efonidipine has been
demonstrated to block the T-type Ca2þ current almost
exclusively in native myocardial cells, Xenopus oocytes, and
BHK cells, whereas the S(þ )-enantiomer blocks both T-type
and L-type Ca2þ current.22,23 Herein, with the use of the
R()-enantiomer of efonidipine, we investigated the role of
the TCC in mediating the development of renal injury in the
remnant kidney model. Furthermore, whether the TCC
activated the Rho/Rho-kinase pathway in the deterioration
process was assessed.
RESULTS
Effect of efonidipine and R()-efonidipine on blood
parameters
At the end of the study, serum creatinine was elevated in
subtotally nephrectomized SHR (SHR-Nx, 0.66±0.12 mg per
100 ml, n¼ 13) compared with sham-operated rats (sham,
0.19±0.01 mg per 100 ml, n¼ 8, Po0.01), and was reduced
in subtotally nephrectomized SHR given efonidipine (SHR-
Nxþ Efo, 0.49±0.03 mg per 100 ml, n¼ 10, Po0.05) and
subtotally nephrectomized SHR given R()-efonidipine
(SHR-NxþR, 0.49±0.02 mg per 100 ml, n¼ 12, Po0.05).
Serum total protein levels did not differ among four groups
(sham, 5.7±0.1 g per 100 ml; SHR-Nx, 5.7±0.2 g per 100 ml;
SHR-Nxþ Efo, 5.8±0.1 g per 100 ml; SHR-NxþR,
5.5±0.1 g per 100 ml, P40.5).
Effect of efonidipine and R()-efonidipine on blood pressure
and proteinuria
After 4 weeks of subtotal nephrectomy, systolic blood
pressure (SBP) in the SHR-Nx group was elevated, compared
with sham (Po0.01), and remained higher throughout the
study period (Figure 1a). Treatment with efonidipine
markedly suppressed the elevated SBP at week 4 (Po0.01
vs SHR-Nx), and did not cause further increases in SBP. In
contrast, R()-efonidipine failed to suppress the elevated
SBP throughout the study period (P40.5 vs SHR-Nx).
Daily urinary protein excretion in SHR-Nx was elevated at
week 4 (Po0.01 vs sham), reaching 96±13 mg day1 at week
8 (Po0.01 vs sham; Figure 1b). Treatment with efonidipine
blunted the increase in proteinuria at week 4 (Po0.05 vs
SHR-Nx) and week 8 (Po0.01 vs SHR-Nx). Similarly, in
SHR-NxþR, the increase in proteinuria was suppressed at
week 4 (Po0.05 vs SHR-Nx), at week 6 (Po0.05), and at
week 8 (Po0.01).
Morphological changes by efonidipine and R()-efonidipine
In SHR-Nx, several glomeruli revealed pathological mani-
festation, including mesangial expansion (Figure 2a).
These alterations were ameliorated by both efonidipine
and R()-efonidipine. Glomerular size was increased in
SHR-Nx, compared with sham (Po0.01; Figure 2b). This
change was restored partially by treatment with efonidipine
and R()-efonidipine (Po0.01 vs SHR-Nx).
Masson-trichrome staining revealed increased levels of
renal interstitial fibrosis and tubular casts in kidneys
from SHR-Nx (Figure 2c). Treatment with efonidipine and
R()-efonidipine markedly suppressed the changes observed
in SHR-Nx (Po0.01). When the tubulointerstitial changes
were semiquantified, it was evident that both agents potently
inhibited the tubulointerstitial fibrosis (Figure 2d).
TCC expression
We examined whether TCC expression was altered in the
remnant kidney. Thus, immunohistochemical analysis
revealed that the expression of a1G, an a1 subunit of the
TCC, was enhanced widely in the kidney, especially in renal
arterioles and glomerular areas, from SHR-Nx (Figure 3a). In
analogy, the expression of a1G was upregulated in the renal
cortical tissues of SHR-Nx, with a 3.2-fold increase compared
with sham (Po0.05; Figure 3b).
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Figure 1 | Effects of efonidipine and R()-efonidipine on the
changes in SBP (a) and urinary protein excretion (b) in subtotally
nephrectomized rats. Open circles: sham; squares: SHR-Nx; triangles:
SHR-Nxþ efonidipine; closed circles: SHR-Nxþ R()-efonidipine.
*Po0.05 vs sham, **Po0.01 vs sham, #Po0.05 vs SHR-Nx, ##Po0.01
vs SHR-Nx.
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To elucidate the role of humoral factors in mediating the
upregulation of a1G expression in renal injury, angiotensin II
(Ang II) and transforming growth factor-b (TGF-b) were
administered in cultured mesangial cells and human kidney
proximal tubular epithelial cells (PTECs), respectively. Thus, Ang
II (100 nmol l1) upregulated a1G expression in mesangial cells,
with a 1.5-fold increase compared with control (n¼ 4, Po0.05;
Figure 3c). Similarly, treatment with TGF-b (5 ng ml1) caused a
1.8-fold increase in a1G expression in PTECs (Figure 3d).
Effect of efonidipine and R()-efonidipine on TGF-b and
Rho-kinase
Immunohistochemical analysis showed an enhanced expres-
sion of TGF-b in the remnant kidney from SHR-Nx (Po0.01
vs sham; Figure 4a and b). Furthermore, the upregulated
TGF-b expression was suppressed by treatment with
R()-efonidipine (SHR-NxþR, Po0.01 vs SHR-Nx), but
not by efonidipine (SHR-Nxþ Efo).
Previously, we demonstrated that the renal cortical tissue
from SHR-Nx manifested enhanced Rho-kinase activity,
which was responsible in part for the progression of renal
injury.11 We therefore investigated whether treatment with
efonidipine and R()-efonidipine affected the Rho/
Rho-kinase pathway in this experimental rat. Thus, the
phosphorylation level of MYPT1, which indicated Rho-
kinase activity, was enhanced in the renal cortical tissue from
SHR-Nx (Po0.01 vs sham) (Figure 5a). Treatment with
efonidipine and R()-efonidipine inhibited the increased
Rho-kinase activity, with similar suppression in SHR-
Nxþ Efo and SHR-NxþR (Po0.01 vs SHR-Nx).
We further evaluated the effect of TGF-b on Rho-kinase
activity and the role of TCCs in TGF-b-mediated Rho-kinase
activation in PTECs. Treatment with TGF-b elicited sub-
stantial activation of Rho-kinase (as assessed by MYPT-1
phosphorylation) in PTECs (Po0.05; Figure 5b). Further-
more, this upregulation was completely prevented by both
efonidipine and R()-efonidipine (Po0.01 vs TGF-b).
Expression of a-smooth muscle actin and vimentin in the
renal cortex
In the renal cortical interstitial area, the expression of
a-smooth muscle actin (a-SMA) was increased in SHR-Nx
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Figure 2 | Effects of efonidipine and R()-efonidipine on morphological changes in subtotally nephrectomized rats. (a) An open
arrow indicates glomerular sclerotic changes in SHR-Nx. (b) Glomerular size in SHR-Nx. (c, d) Interstitial fibrosis and tubular casts in kidneys from
SHR-Nx. **Po0.01 vs sham, ##Po0.01 vs SHR-Nx. (a, b: periodic acid-Schiff (PAS) stain; c, d: Masson-trichrome stain).
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Figure 3 | a1G expression in the renal cortex of subtotally nephrectomized rats, rat mesangial cells, and PTECs.
(a) Immunohistochemistry for a1G expression in kidneys from SHR-Nx. (b) Immunoblot for a1G protein in kidneys from SHR-Nx.
(c) Upregulation of a1G expression by Ang II in cultured mesangial cells. (d) Upregulation of a1G expression by TGF-b in PTECs. *Po0.05 vs
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Figure 4 | Effects of efonidipine and R()-efonidipine on renal TGF-b expression in subtotally nephrectomized rats.
(a) Immunohistochemical analysis for TGF-b expression in the renal cortical tubulointerstitial area of SHR-Nx. (b) Effects of CCBs on the
expression of TGF-b-positive cells. **Po0.01 vs sham, ##Po0.01 vs SHR-Nx.
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(Po0.01 vs sham; Figure 6a and b). Treatment with
efonidipine and R()-efonidipine completely suppressed
the enhanced expression of a-SMA (Po0.05 vs SHR-Nx).
The expression of vimentin was also enhanced in the
tubulointerstitial area in SHR-Nx (Po0.01 vs sham; Figure
6c and d). The enhanced expression of vimentin was
markedly downregulated in SHR-Nxþ Efo and SHR-NxþR
(Po0.01 vs SHR-Nx). No significant difference in vimentin
expression levels was observed between SHR-Nxþ Efo and
SHR-NxþR.
DISCUSSION
A large amount of evidence has been accumulated that
lowering systemic blood pressure constitutes a pivotal
determinant of renal protection in the treatment of
hypertension. Renal protection is also afforded by the
correction of glomerular hypertension with specific agents
that elicit vasodilation of the postglomerular (i.e., efferent)
arteriole. Our previous study demonstrated that efonidipine
improved renal injury much more than nifedipine in
subtotally nephrectomized SHR, although both CCBs equally
lowered SBP.10 These data suggest that the renal protective
effect of efonidipine results from its salutary action on
glomerular hemodynamics independent of SBP, based on the
finding that efonidipine elicits dilation of the efferent as well
as the afferent arteriole. Nevertheless, it has not been
determined whether the renal protective action of efonidi-
pine depends on the inhibition of TCC activity, because
efonidipine has the ability to block both TCCs and LCCs.
This study has demonstrated that efonidipine improves
proteinuria and glomerular hypertrophy and reduces SBP in
subtotally nephrectomized SHR. As subtotal nephrectomy
predisposes the afferent arteriole to vasodilation24 and the
effect of CCBs on the afferent arteriolar tone may not be
apparent in chronic renal disease, it can be speculated that
the glomerular capillary pressure is determined by the
systemic blood pressure and the efferent arteriolar tone.
Thus, the beneficial action of efonidipine on glomerular
hemodynamics may depend on a marked reduction in blood
pressure and the efferent arteriolar dilation.2,4,7,10 In contrast,
R()-efonidipine, a specific T-CCB, fails to lower blood
pressure but ameliorates proteinuria and glomerular hyper-
trophy to the same extent as efonidipine (Figures 1 and 2).
Because R()-efonidipine possesses more potent inhibitory
activity on TCCs than efonidipine,23 efferent arteriolar
dilation could play a major role in preventing glomerular
hypertrophy. In concert, our findings clearly indicate that
specific blockade of TCCs offers renal protective action
independent of systemic blood pressure.
Alternatively, the T-CCB may directly prevent the
pathological process of renal injury. This study demonstrates
that the renal tissue from SHR-Nx manifests enhanced
expression of a1G subunits of the TCC (Figure 3a and b).
Furthermore, in cultured mesangial cells, the expression of
a1G is upregulated by Ang II (Figure 3c). Ang II constitutes a
pivotal vasoactive substance involved in the progression of
renal injury,25 and the renal Ang II content is increased in
renal injury induced by five-sixths nephrectomized rats.26
Moreover, TGF-b, which is enhanced and is responsible for
the development of renal injury,27 upregulates a1G expres-
sion (Figure 3d). Our current observation therefore implies
that the blockade of TCCs would provide exaggerated
mitigatory action on the progression of glomerular injury.
Furthermore, it has been reported that mibefradil, a mixed
TCC and LCC blocker, improves proteinuria and glomerular
damage in DOCA-salt rats whereas amlodipine fails to blunt
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Figure 5 | Effects of efonidipine and R()-efonidipine on renal Rho-kinase activity and TGF-b-induced Rho-kinase upregulation. (a) The
phosphorylation level of MYPT1, as a marker for Rho-kinase activity, in the renal cortex of SHR-Nx. *Po0.05 vs sham, ##Po0.01 vs SHR-Nx.
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the progression of renal injury.28 Of note, both amlodipine
and mibefradil exert similar antihypertensive actions and
decrease glomerular capillary pressure to the same level. It
appears therefore that the T-CCB confers greater benefit
distinct from that provided by the L-CCB. In concert,
available evidence indicates that the TCC per se regulates
glomerular pathological process, which does not absolutely
require the effect on systemic blood pressure or glomerular
capillary pressure for the renal action of the TCC.
The expression of the TCC has been reported in several
pathological conditions. It has been demonstrated that TCCs
are expressed in the fetal myocardium29 and in the condition
of morbid cardiac muscle, such as cardiac hypertrophy30 and
heart failure.31 In our model of subtotally nephrectomized
SHR, the expression level of a1G subunits of the TCC is
markedly upregulated (Figure 3a and b). These results
support the idea that the T-CCB has the potential to block
the pathological processes, and suggest the role of the TCC in
‘atavism’ of damaged organs. In the morbid state, the
suppression of the TCC might be exceedingly important for
arresting the process that builds up vicious circle. Indeed,
Ang II is reported to increase T-type Ca2þ current and TCC
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Figure 6 | Effects of efonidipine and R()-efonidipine on renal expressions of a-SMA and vimentin in kidneys from subtotally
nephrectomized rats. (a) Arrowheads indicate a-SMA-positive cells in the renal cortical interstitial area of SHR-Nx. (b) Effects of Ca2þ
channel blockers on the expression of a-SMA in the renal cortical area of SHR-Nx. (c) Arrows indicate vimentin expression in the
tubulointerstitial area of SHR-Nx. (d) Suppressed expression of vimentin in SHR-Nxþ Efo and SHR-Nxþ R. **Po0.01 vs sham, #Po0.05 vs
SHR-Nx, ##Po0.01 vs SHR-Nx. ( 400 magnification).
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expression in cardiac cells.32 We therefore propose that
exaggerated TCC expression plays a substantial role in Ang
II-associated organ damage. Further studies are required to
elucidate the role of the TCC in Ang II-associated organ
remodeling and cellular phenotypic changes.
Although it is well established that TGF-b plays a crucial
role in the progression of renal fibrosis, the mechanism
whereby TCCs affect renal tubulointerstitial fibrotic process
remains undetermined. In this study, we observed enhanced
expression levels of TGF-b, particularly in the interstitial area
of kidneys from SHR-Nx, and the increased TGF-b expres-
sion was prevented by a specific TCC-B, R()-efonidipine,
and tended to be suppressed by efonidipine (Figure 4a and
b). These observations suggest that TCCs participate in the
induction of TGF-b and the subsequent renal fibrosis. In this
regard, amlodipine, a CCB with L-type and N-type calcium
channel blocking activity, is reported to stimulate TGF-b
production in human mononuclear cells.33 Thus, the failure
of efonidipine to suppress renal TGF-b expression might be
related to variable degrees of blocking activity on the TCC
and LCC.
This study demonstrates that Rho-kinase is activated
in SHR-Nx and is suppressed by efonidipine and
R()-efonidipine (Figure 5a). In this regard, we have recently
shown that Ang II-induced activation of Rho-kinase is
inhibited by efonidipine and mibefradil but not by nifedipine
in vascular smooth muscle cells (unpublished observation).
Furthermore, R()-efonidipine blunts the Ang II-induced
enhancement in GTP-Rho. As Ang II is responsible in large
part for TGF-b stimulation and the aggravation and/or
initiation of renal injury, TCCs may mediate or modulate the
activation of Rho/Rho-kinase in renal injury. Of note, a
growing body of evidence has been accumulated that the
Rho/Rho-kinase pathway participates in the control of
glomerular hemodynamics17 and the pathological process
of renal disease.11,12 We have recently demonstrated that
fasudil, a Rho-kinase inhibitor, improves renal injury in
subtotally nephrectomized SHR.11 Moreover, the Rho/
Rho-kinase pathway is involved in the development of
tubulointerstitial fibrosis.34 Finally, this study shows that
TGF-b stimulates Rho-kinase activity in PTECs and this
effect is inhibited by T-CCBs (Figure 5b). Previous studies
demonstrated that Rho-kinase plays a substantial role not
only in inducing TGF-b12,13,35 but also in mediating the renal
tubular action of TGF-b.36 It is thus conjectured that T-CCBs
ameliorate renal tubulointerstitial fibrosis, and the suppres-
sion of the Rho/Rho-kinase pathway by T-CCBs is respon-
sible in part for the improvement of this pathological process.
Of note, this study shows that R()-efonidipine amelio-
rates renal injury with no appreciable effect on blood
pressure. As Rho-kinase is one of the important factors
causing hypertension, the suppression of the Rho/Rho-kinase
pathway by T-CCBs might efficiently correct hypertension in
this experiment. In our previous study using the rat remnant
kidney model, however, fasudil reduced proteinuria, but
failed to induce a significant decrease in blood pressure.11
Another study also demonstrates that fasudil significantly
improves renal function, proteinuria, and histological find-
ings, without changing blood pressure in Dahl salt-sensitive
rats.12 Thus, the inhibition of TCCs and Rho-kinase may
offer renal protection, which may not exclusively require a
reduction in systemic blood pressure.
The role of epithelial–mesenchymal transition (EMT) in
renal fibrosis merits comments. This study demonstrates that
subtotal nephrectomy induces renal tubulointerstitial fibrosis
(Figure 2) and upregulates the expression of a-SMA and
vimentin (Figure 6). Furthermore, these changes are inhibited
by treatment with efonidipine and R()-efonidipine. Once
epithelial cells acquire mesenchymal phenotypic character-
istics, the expression levels of a-SMA and vimentin are
increased,37,38 which implies enhanced mesenchymal
transdifferentiation of tubular epithelial cells39 and the
subsequent tubulointerstitial fibrosis. To the extent that
activation of Rho-GTPase serves as an important mechanism
for EMT,40 the potent inhibitory action of T-CCBs on
Rho-kinase would halt the process of EMT and alleviate renal
tubulointerstitial fibrosis. Of interest, treatment with efonidi-
pine or R()-efonidipine mitigates but does not completely
abolish the activated Rho-kinase observed in SHR-Nx,
whereas it nearly totally suppresses the expression of a-SMA
and vimentin. It is surmised therefore that other mechanisms
contribute to the inhibition of EMT and fibrosis, including
the suppression of nuclear factor-kB20 and cell proliferation.41
In summary, the blockade of the TCC exerts potent renal
protective action, reflected by the suppression of glomerular
hypertrophy and tubulointerstitial fibrosis in the model of
chronic kidney disease. The beneficial action does not
absolutely require a reduction in systemic blood pressure,
but is mediated by multiple mechanisms, including inhibi-
tion of EMT, in which activation of the Rho/Rho-kinase
pathway is involved (Figure 7). Finally, as TCCs are
upregulated in the chronic renal injury model, T-CCBs may
constitute a novel therapeutic tool for the treatment of
chronic kidney disease.
MATERIALS AND METHODS
Animal preparations
Six-week-old male SHR (n¼ 43) (Japan SLC Inc., Shizuoka, Japan)
were placed in individual metabolic cages and were initially fed a
standard rat chow (15 g day1; Nippon Clea, Tokyo, Japan)
containing 0.3% NaCl, 0.74% potassium, and 20.6% protein, and
were given water ad libitum. Subtotal nephrectomy was performed
by removal of two-thirds of the left kidney (week 0), followed by
total right nephrectomy (week 1) under ether anesthesia. Rats were
then randomly assigned to four groups: group 1, sham-operated rats
(sham, n¼ 8); group 2, subtotally nephrectomized rats (SHR-Nx,
n¼ 13); group 3, SHR-Nx given efonidipine (Efo, 100 mg per kg per
day, n¼ 10; Nissan Chemical Industries, Tokyo, Japan), and group 4,
SHR-Nx given R()-efonidipine (R, 100 mg per kg per day, n¼ 12;
Nissan Chemical Industries). SBP, measured by the tail-cuff method,
and daily urinary protein excretion were evaluated every other week.
At week 8, rats in each group were decapitated in the morning under
the fasting condition. Blood was collected, and serum total protein
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and creatinine were measured by an autoanalyzer. The kidneys were
harvested for further analysis. All experiments were performed in
accordance with the animal experimentation guidelines of Keio
University School of Medicine.
Morphological examination
Each paraffin section of rat kidneys was stained with periodic acid-
Schiff and Masson-trichrome stain. Glomerular changes were
assessed as the size of mesangial and vascular areas at the level of
vascular pole using a computer-aided manipulator (microscope,
Leica DM4000B; camera, Leica DFC300FX; software, Leica IM500).
Tubulointerstitial fibrotic areas stained in light blue with Masson-
trichrome stain were picked on the digital images using a computer-
aided manipulator, and were graded as follows: 0, none; þ 1,
o25%; þ 2, 25–50%; þ 3, 450%. The scores were determined in
each section selected at random and more than 15 fields were
examined under  400 magnification. Morphological evaluation
was conducted by two independent observers in a blinded fashion.
Immunohistochemistry
Immunohistochemical analysis for renal fibrosis was performed
using antibodies against a-SMA (Dako Cytomation, Glostrup,
Denmark) and vimentin (Dako). a-SMA-positive cells, vimentin-
positive cells, and TGF-b-positive cells were counted and graded as
follows: 0, none; þ 1,o25%; þ 2, 25–50%; þ 3, 450% of a-SMA-
or vimentin-positive area. We further examined whether the
expression of the TCC was altered in kidneys from SHR-Nx.
Immunohistochemical evaluation was conducted using an antibody
against a1G subunits of the TCC (Santa Cruz Biotechnology, Santa
Cruz, CA, USA).
Cell culture
Mesangial cells were prepared from 3-week-old male Sprague–Dawley
rats, using the mesh sieving technique. Briefly, the renal cortical tissue
was removed, washed with Hank’s balanced salt solution (Nissui
pharmaceutical Co, Ltd, Tokyo, Japan), and passed through 212 and
150mm mesh sieves. Glomeruli were finally recovered after sieving
through a 53mm mesh filter. The cells were cultured in D-MEM/F-12
medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal calf
serum (Biological Industries, Kibbutz Beit Haemek, Israel), 10ml ml1
ITSþ culture supplement (Becton Dickinson, Frankin Lakes, NJ,
USA), 100 U ml1 penicillin (Invitrogen), 100 mg ml1 streptomycin
(Invitrogen), and 200 mmol l1 L-glutamine (Invitrogen). Early
passaged (passages 4–8) mesangial cells were grown to 60–70%
confluence and made quiescent by serum starvation for 24 h. Ang II
(100 nmol l1; Sigma, St Louis, MO, USA) was added and the cells
were harvested after 24 h of Ang II treatment.
PTECs (Cambrex Bio Science Walkersville Inc., Walkersville,
MD, USA) were cultured in renal epithelial cell basal medium
(Cambrex Bio Science Walkersville Inc.) supplemented with
0.5 mg ml1 hydrocortisone, 10 ng ml1 human recombinant epider-
mal growth factor, 5 mg ml1 insulin, 0.5 mg ml1 epinephrine,
6.5 ng ml1 triiodothyronine, 10 mg ml1 transferrin, 0.5 ml GA-
1000, 0.5% fetal bovine serum, 100 U ml1 penicillin (Invitrogen),
100 mg ml1 streptomycin (Invitrogen), and 200 mmol l1 L-gluta-
mine (Invitrogen). Each cell was grown at 371C in 5% CO2 and the
medium was changed every other day. After starvation, recombinant
human TGF-b1 (R&D Systems, Minneapolis, MN, USA) was added
before the treatment of efonidipine or R()-efonidipine, and the
cells were harvested after 24 h of TGF-b treatment.
Immunoblotting
Renal cortical tissues, mesangial cells, and PTECs were lysed
and fornicated in solubilization buffer. Immunoblotting was
performed as described previously,42 using specific antibodies
against phospho-MYPT1 (Upstate Biochemistry, Lake Placid, NY,
USA) and a1G (Alomone, Jerusalem, Israel). Immunoreactive bands
were detected using an ECL detection kit (Amersham Biosciences,
Uppsala, Sweden). Immunoblots were analyzed by computer-aided
planimetry using the Scion Image software (Scion Corp., Fredrick,
MD, USA). In detail, images were digitized and captured with a
CCD camera connected to a personal computer, and scanned into
Photoshop (Adobe Systems, San Jose, CA, USA). A binary overlay
was created automatically, and the threshold of the binary overlays
was adjusted by comparing image to optimal match of each spot.
The value of the threshold setting was kept constant.
Statistical analysis
Data were expressed as the mean±s.e.m. Data were analyzed
by one- or two-way analysis of variance as appropriate, followed by
Newman–Keuls post hoc test. Histological results were analyzed
by Kruskal–Wallis nonparametric test. Po0.05 was considered
statistically significant.
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